U.S. markets open in 1 hour 32 minutes
  • S&P Futures

    4,168.75
    +15.25 (+0.37%)
     
  • Dow Futures

    33,338.00
    +183.00 (+0.55%)
     
  • Nasdaq Futures

    14,065.25
    +30.25 (+0.22%)
     
  • Russell 2000 Futures

    2,245.00
    +14.40 (+0.65%)
     
  • Crude Oil

    71.71
    +0.07 (+0.10%)
     
  • Gold

    1,782.80
    +13.80 (+0.78%)
     
  • Silver

    26.08
    +0.11 (+0.43%)
     
  • EUR/USD

    1.1896
    +0.0031 (+0.26%)
     
  • 10-Yr Bond

    1.4500
    0.0000 (0.00%)
     
  • Vix

    20.44
    +2.69 (+15.15%)
     
  • GBP/USD

    1.3876
    +0.0067 (+0.48%)
     
  • USD/JPY

    110.1060
    -0.0440 (-0.04%)
     
  • BTC-USD

    32,471.99
    -1,474.60 (-4.34%)
     
  • CMC Crypto 200

    796.83
    -143.12 (-15.23%)
     
  • FTSE 100

    7,012.79
    -4.68 (-0.07%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

MedTech Round Up: Update On Lucira Health, Second Sight Medical ClearPoint Neuro, Medtronic, Sientra

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Lucira Health Inc (NASDAQ: LHDX) has announced that its Lucira Check IT COVID-19 test kit is now available on Amazon.com in the US.

  • Each Lucira Check IT test kit provides a PCR quality test result at home in 30 minutes or less. The product costs $55.

  • Price Action: LHDX shares are trading 14.3% higher at $5.82 during the market session on the last check Wednesday.

Second Sight Medical Products Inc (NASDAQ: EYES) has announced two-year results of its Early Feasibility Study of the Orion Visual Cortical Prosthesis.

  • Data showed that all five patients tested at the two-year mark could locate a white square on a dark computer screen significantly better with the Orion System on than with it off.

  • 4/5 were able to identify better the direction of motion of a bar moving across a computer screen.

  • Orion is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes.

  • Price Action: EYES shares are trading 43.6% higher at $7.18 during the market session on the last check Wednesday.

View more earnings on CLPT

ClearPoint Neuro Inc (NASDAQ: CLPT) announced FDA clearance for its SmartFrame Array, a navigation system designed for use in both the MRI suite and operating room.

  • The company reported Q1 sales of $4.03 million, which beat the analyst consensus estimate of $3.27 million, and up 29% Y/Y.

  • It sees sales in the range of $16-$17.5 million for the 2021 calendar year, better than the consensus of $15.83 million.

  • Price Action: CLPT shares are trading 1.67% higher at $17.96 during the premarket session on the last check Wednesday.

Medtronic Plc (NYSE: MDT) is recalling HeartWare HVAD System to provide updated Instructions due to safety issues with Carrying Cases, Driveline Cover Orientation, and Controller Power-Up Sequence.

  • HVAD System helps the heart continue to pump blood to the rest of the body.

  • The faulty devices may cause serious patient harm, including death.

  • There have been one death and 64 injuries reported to the FDA for these issues.

  • Price Action: MDT shares are trading 1.56% lower at $123.27 during the market session on the last check Wednesday.

Sientra Inc (NASDAQ: SIEN) has agreed to sell its miraDry business to 1315 Capital, a healthcare growth equity firm. Deal terms were not disclosed.

  • The miraDry system provides a non-invasive treatment that offers a lasting solution for underarm sweat.

  • It reported Q1 2021 sales of $23.2 million, a 37% Y/Y increase and beating the consensus estimate of $18.8 million.

  • Sientra sees full-year 2021 breast products sales in the range of $72 to $76 million, representing 31%-38% growth Y/Y, compared to previous guidance of $70 million to $74 million.

  • Price Action: SIEN shares are trading 5.3% lower at $6.38 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.